Amniotics Investor Relations Material
Latest events
Q2 2024
20 Aug, 2024
Q4 2023
22 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Amniotics
Access all reports
Amniotics AB is a Swedish biotechnology company focused on developing stem cell-based therapeutics for severe, life-threatening diseases. The company specializes in mesenchymal stem cells (MSCs) derived from amniotic fluid, which are used to create targeted treatments for various conditions. Amniotics has developed several product candidates, including PulmoStem, aimed at treating lung diseases, CogniStem for central nervous system disorders, NephroStem for kidney conditions, and CutiStem for skin therapies. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
AMNI
Country
🇸🇪 Sweden